|
Daniel is the Managing Director and Partner of Fidelity Asia Ventures (FAV). He has over 20 years of experience as a venture professional investing in companies throughout Asia, with a focus on Greater China. Since late 1994, he has been Managing Director of the two principal entities responsible for Fidelity's Asian venture capital activity, headquartered in Hong Kong.From 1987 to 1994, Daniel was a Partner at Arral and Partners (Asia) Limited, an early pioneer venture capital firm based in Hong Kong, associated with having made landmark investments around the Asia region at the early stages of the private equity industry.From 1981 to 1985, Daniel was an analyst in the equity research department of Fidelity Investments in Boston and portfolio management assistant for the Fidelity Magellan Fund.On behalf of FAV, Daniel is currently on the Board of Directors of Asia Renal Care Ltd (Chairman), Wuxi Pharmatech, Dianji Technology Holdings Ltd., UIM Holdings and CDP.Until recently, prior to FAV's successful exits, Daniel held board positions on several other leading Chinese technology companies, including Alibaba (acquired Yahoo! China), Asiainfo (NASDAQ ASIA), BMI and Hurray! Holdings (NASDAQ HRAY). Daniel's role on the board of these companies spanned a wide range of areas, in each case representing deep involvement in most aspects of their businesses during every key phase of their development.Daniel holds an MBA degree from the Harvard Graduate School of Business and a Bachelor of Arts degree from Dartmouth College | 